Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 2018
Event: Entry into a Material Definitive Agreement and creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
This filing details a private placement financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Principal Amount: $105,000
- Net Proceeds: $100,000 (after a $5,000 deduction for legal expenses)
- Interest Rate: 8% per annum (payable in shares upon conversion)
- Maturity Date: November 30, 2019
- Closing Date: December 3, 2018
- Use of Proceeds: General working capital
Material Changes and Instrument Terms
The Company entered into a Securities Purchase Agreement with Eagle Equities, LLC for a convertible promissory note. Material terms include:
- Conversion Option: Eagle Equities may convert principal and interest into common stock after six months.
- Conversion Price: 61% of the lowest closing bid price of the prior ten trading days. This drops to 51% if the stock is restricted by the Depository Trust Company.
- Prepayment Penalties:
- Within 90 days: 115% of principal plus accrued interest.
- Between 90 and 181 days: 125% of principal plus accrued interest.
- Change of Control: Upon asset transfer or merger, the note may be redeemed for 150% of principal plus accrued interest.
- Default Interest: Increases to 24% per annum (or highest rate permitted by law) upon an event of default.
Default Penalties and Risks
The note contains aggressive penalty clauses that increase the principal obligation under specific adverse conditions:
- Liquidated Damages: $250/day for days 4-9 of delayed share issuance; $500/day thereafter.
- Loss of Bid Price: Principal increases by 20%.
- Delisting or Reporting Failure: Principal increases by 50% if the stock is delisted, trading is suspended for >10 days, or reporting obligations are not met.
- Reporting Delinquency: If delinquent after six months, the conversion base price is set to the lowest close during the delinquency period.
Outlook and Management Commentary
The filing does not provide forward-looking guidance, revenue projections, or management commentary regarding future business strategy beyond the immediate use of proceeds for working capital. The transaction was executed as a private placement under Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the current trading status and bid price of Propanc Biopharma common stock on the OTC Markets Group to assess the potential dilution impact of the 61% conversion discount.
- Confirm the Company's compliance with periodic reporting obligations under the Exchange Act to avoid the 50% principal penalty.
- Review the Company's cash position to determine the ability to service the 8% interest (payable in shares) or prepay the note without incurring significant premiums.
- Check for any existing restrictions on the Company's stock by the Depository Trust Company, which would trigger the lower 51% conversion price.
- Assess the total outstanding shares to ensure the 4.99% beneficial ownership limit for Eagle Equities is not breached upon conversion.